Autologous Transplantation
refers to the use of the patient's own bone marrow or stem cells previouslyharvested usually at the time of remission and stored in liquid nitrogen.The administration of high doses (5-10X standard conventional doses) ofchemotherapy or Total Body Irradiation is expected to induce tumor cellkill but is also associated with prolonged or permanent bone marrow failure.The stored bone marrow or stem cells are thawed and reinfused in orderto "rescue" the patient from such bone marrow failure. Adequatebone marrow recovery generally takes 2-3 weeks after reinfusion and mayeven be faster if peripheral blood stem cells are utilized rather thanbone marrow. In certain selected cases this entire procedure could be performedon an outpatient basis without any added risk or negative alteration ofoutcome.
Treatment Protocols and Clinical Trials using AutologousTransplantation are available for the following disorders:
- Breast Cancer
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Testicular Cancer
- Ovarian Cancer
- Neuroblastoma
- Multiple Myeloma
- Other rare disorders
Allogeneic Transplantation
makes use of another person's cells to replace the patient's own bonemarrow. The donor could be a twin (Syngeneic Transplant) or a non-twinsibling who either closely or completely matches the patient's HLA (HumanLeukocyte Antigen) tissue type. For those who do not have suitable siblingdonors, parents or children of the patient rarely could become closelymatched donors. Otherwise, a search through international donor registriescould frequently come up with a HLA-matched unrelated donor. Traditionally,bone marrow is collected from the donor and used for transplantation butrecently, donor stem cells harvested from the peripheral blood is alsobeing used in place of marrow. Umbilical Cord blood is also increasinglybeing utilized in children or patients under 40 kg.
Treatment Protocols or Clinical Trials involving AllogeneicTransplantation are available for the following disorders:
- Severe Aplastic Anemia
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Severe Combined Immunodeficiency Disease
- Other rare disorders
To refer a patient or for more information on theabove protocols contact:
OUHSC-Columbia/Presbyterian BMT Program
920 SL Young Blvd WP2010
Oklahoma City, OK 73104Phone (405)271-4022
Fax (405)271-3020
E-mail: hem-onc@uokhsc.edu